Next-generation antithrombotics in ischemic stroke: preclinical perspective on ‘bleeding-free antithrombosis'

The present antithrombotic drugs used to treat or prevent ischemic stroke have significant limitations: either they show only moderate efficacy (platelet inhibitors), or they significantly increase the risk for hemorrhages (thrombolytics, anticoagulants). Although most strokes are caused by thrombot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraft, Peter, De Meyer, Simon F, Kleinschnitz, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463876/
https://www.ncbi.nlm.nih.gov/pubmed/22805877
http://dx.doi.org/10.1038/jcbfm.2012.108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463876/
https://www.ncbi.nlm.nih.gov/pubmed/22805877
http://dx.doi.org/10.1038/jcbfm.2012.108

Ejemplares similares